for 5 days as previously described. 2 
Immunoblot analysis
Cell pellets were lysed using ice-cold RIPA-Buffer (Sigma-Aldrich) supplemented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich and Thermo Fisher Scientific).
Immunoblots were then performed as previously described 3 employing Mini-PROTEAN TGX gels for electrophoresis (Bio-Rad) and the Bio-Rad Trans Blot TurboBlotting System for transfer. Polyvinylidene difluoride membranes (Bio-Rad) were incubated with anti-RKIP (Merck Millipore), anti-GFP-RKIP (Cell Signaling), anti-ERK (Sigma-Aldrich), anti-pERK (Cell Signaling), anti-β-actin (Sigma-Aldrich) and anti-Vinculin (Abcam). The intensity of the bands was compared using ImageJ. 4 RKIP loss in CMML patient samples was defined as previously reported for AML.
3

RNA extraction, reverse transcription and real time quantitative PCR
RNA was isolated from primary CMML patient samples using TRIzol (Thermo Fisher Scientific), and from hematopoietic cells of healthy donors as well as from umbilical cord blood employing the miRNAeasy Micro Kit (Qiagen) following the manufacturer´s instruction.
cDNA synthesis was performed with TaqMan Reverse Transcription (RT) Reagents (Applied Biosystems) starting from 400 ng of total RNA and using random hexamers for RT. An
Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems) and the SYBR Green method (Invitrogen) were used for real time quantitative PCR (qPCR) for RKIP mRNA expression analysis. B2M and GAPDH were selected as control genes for the analyses performed and NB4 AML cells served as calibrator. The expression levels were evaluated employing the comparative ddCT method as previously described. 
Flow cytometry
Flow cytometry was performed as previously described using the following antibody panels:
efluor-CD11b (eBiosciences), PE-Cy7-Ly6G (eBiosciences), APC-CD117 (eBiosciences) and 
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Mx1-Cre/Nras/Rkip +/+ Mx1-Cre/Nras/Rkip -/- Hct, hematocrit; PLT, platelets). In addition, the presence and severity of histiocytic sarcoma (HS), myeloproliferation (MP) and myeloproliferative disease (MPD), respectively, is displayed. In more detail, MPD was defined as either present (+) or absent (-), as defined previously. 9 For grading the extension of MP, we used a slightly adapted scoring system from Lacroix-Triki et al., 10 where the average amount of hematopoietic foci per one 100x field was evaluated in the liver and spleen and scored as follows: 0 = absent, + = 1-2 hematopoietic foci, ++ = 3-4 hematopoietic foci and +++ = >4 hematopoietic foci. For HS, we used a scoring system, which includes both the amount of organs infiltrated and the extension of organ infiltration. Due to the absence of a previously established protocol, we thereby routinely analysed bone marrow, spleen, liver, lymph nodes and the thymus for the presence of HS (as defined by the Bethesda classification of nonlymphoid hematopoietic neoplasms in mice). 9 As organ infiltration was either very low or very high in all samples studied, we arbitrarily defined extensive infiltration of an organ, when more than 50% HS infiltration was present. Due to a generally lower infiltration rate, this cut-off was lowered to >30% infiltration in the liver. Subsequently, the extension of HS was defined as follows: 0 = no HS in any of the organs, "+" = HS present, but extensive organ infiltration in <3 of the 5 organs studied;
"++" = extensive organ infiltration in ≥3 of the 5 organs studied. Supplemental Table 5 . Detailed list of RAS mutations identified within this study. The 
